Currently, in clinical trials are 2nd and 3rd generation CARs designed to target a wide variety of antigens expressed on solid tumors, including among others the HER2 and EGFR-positive malignancies, carcinoembryonic antigen (CEA) for metastatic tumors of various origin, PCMA antigen for prostate cancer, EGFRvIII for glioblastoma, GD2 and Li-CAM for neuroblastoma, VEGFR-II and cMet for melanoma, Muc-1 for various malignancies and GPC3 for hepatocellular carcinoma [235,262,263]. Here, CEACAM5 is linked to neuroblastoma.